Marco Guevara-Aguirre
Overview
Explore the profile of Marco Guevara-Aguirre including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
461
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Guevara-Aguirre J, Procel P, Guevara C, Guevara-Aguirre M, Rosado V, Teran E
Growth Horm IGF Res
. 2015 Aug;
28:76-8.
PMID: 26259979
In the present pandemics of obesity and insulin resistant diabetes mellitus (DM), the specific contribution of etiological factors such as shifts in nutritional and exercise patterns, genetic and hormonal, is...
2.
Guevara-Aguirre J, Rosenbloom A, Balasubramanian P, Teran E, Guevara-Aguirre M, Guevara C, et al.
J Clin Endocrinol Metab
. 2015 May;
100(7):2589-96.
PMID: 25985182
Context: Ecuadorian subjects with GH receptor deficiency (GHRD) have not developed diabetes, despite obesity. Objective: We sought to determine the metabolic associations for this phenomenon. Design: Four studies were carried...
3.
Kerns S, Guevara-Aguirre J, Andrew S, Geng J, Guevara C, Guevara-Aguirre M, et al.
J Clin Endocrinol Metab
. 2014 Jul;
99(10):E2117-22.
PMID: 25057881
Context: CDKN1C, a cyclin-dependent kinase inhibitor and negative regulator of cellular proliferation, is paternally imprinted and has been shown to regulate β-cell proliferation. CDKN1C mutations are associated with growth disorders,...
4.
Guevara-Aguirre J, Rosenbloom A, Guevara-Aguirre M, Saavedra J, Procel P
J Clin Endocrinol Metab
. 2013 Jan;
98(2):839-45.
PMID: 23341492
Context: The maximum dose of IGF-I recommended for treatment of GH insensitivity is commonly used. Objective: The aim was to test the hypothesis that a lower dose is as effective...
5.
Guevara-Aguirre J, Guevara-Aguirre M, Hwa V, Procel P, Saavedra J, Ostrer H, et al.
Eur J Endocrinol
. 2011 Dec;
166(3):521-9.
PMID: 22170795
Objective: To describe the clinical and biochemical features, and perform molecular analysis for candidate abnormalities in a novel familial syndrome of intrauterine growth retardation (IUGR), failure of an adolescent growth...
6.
Guevara-Aguirre J, Balasubramanian P, Guevara-Aguirre M, Wei M, Madia F, Cheng C, et al.
Sci Transl Med
. 2011 Feb;
3(70):70ra13.
PMID: 21325617
Mutations in growth signaling pathways extend life span, as well as protect against age-dependent DNA damage in yeast and decrease insulin resistance and cancer in mice. To test their effect...
7.
Guevara-Aguirre J, Guevara-Aguirre M, Saavedra J, Bernstein G, Rosenbloom A
Diabetes Technol Ther
. 2007 Aug;
9(4):372-6.
PMID: 17705693
Background: The aim of this study was to compare the glucose pharmacodynamics after oral spray insulin (Oral-lyn , Generex Biotechnology, Toronto, ON, Canada) and subcutaneous (sc) injection of regular insulin...
8.
Guevara-Aguirre J, Rosenbloom A, Guevara-Aguirre M, Yariz K, Saavedra J, Baumbach L, et al.
Growth Horm IGF Res
. 2007 Mar;
17(3):261-4.
PMID: 17350302
Context & Objective: The Ecuadorian GH receptor deficiency (GHRD)/Laron syndrome population is the only large cohort with a single GHR mutation (E180 splice), permitting identification of numerous carrier and noncarrier...
9.
Guevara-Aguirre J, Guevara-Aguirre M, Rosenbloom A
Acta Paediatr
. 2006 Feb;
95(2):199-202.
PMID: 16449027
Aim: To determine whether recombinant human insulin-like growth factor-I (rhIGF-I) administration to children with low IGF-I and relatively low insulin-like growth factor binding protein-3 (IGFBP3) serum concentrations would result in...